ABAC Therapeutics develops targeted antibiotics that specifically combat severe bacterial infections resistant to standard treatments. By utilizing advanced drug design techniques, the company aims to improve patient outcomes and reduce the duration of hospital stays for affected individuals.

ABLE develops lightweight robotic exoskeletons designed for neurorehabilitation, enabling individuals with mobility impairments to regain the ability to walk. The exoskeletons facilitate rapid adjustment and intuitive use, significantly improving therapy efficiency and enhancing the quality of life for users.

ADmit Therapeutics is developing a diagnostic test that identifies biomarkers unrelated to β-amyloid and tau for the early detection of Alzheimer's disease. This technology aims to facilitate timely diagnosis, enabling earlier intervention and improved patient outcomes.

Anaconda Biomed develops a catheter system designed for mechanical thrombectomies, utilizing a nitinol braided funnel to enhance clot retention and minimize fragmentation during retrieval. This technology addresses the critical need for effective stroke intervention by improving the efficiency and safety of clot removal in patients with acute ischemic stroke.

AptaTargets is a clinical-stage biopharmaceutical company developing therapeutic aptamers to target inflammation in acute medical conditions such as ischemic stroke and myocardial infarction. Their lead candidate, ApTOLL, uniquely inhibits TLR4 activation to provide neuroprotection during the acute phase of stroke, addressing significant damage caused by inflammatory responses.

Corify Care has developed ACORYS®, a non-invasive cardiac mapping system that enables clinicians to perform real-time, beat-to-beat global cardiac mapping in under 10 minutes. This technology addresses the limitations of traditional catheter-based mapping by providing a comprehensive view of the entire heart, enhancing diagnostic accuracy and patient safety.

This biotechnology company specializes in the early diagnosis of ocular pathologies through the use of specific biomarkers, focusing on corneal diseases. By developing targeted treatments, the company aims to enhance corneal integrity and improve patients' quality of life.

Alya Red is a virtual human that employs machine learning algorithms to analyze individual health data and create personalized medical treatment plans. This technology aims to enhance treatment efficacy and improve patient outcomes, ultimately increasing patients' longevity.

The startup develops medical treatments and diagnostic tools targeting acute myeloid leukaemia (AML) by identifying a novel therapeutic target against leukemic stem cells. Their approach utilizes a repurposed small molecule to enhance diagnosis and prognosis for AML patients, aiming to improve treatment outcomes for this critical disease.

MJN develops the mjn-SERAS device, which utilizes real-time monitoring technology to predict epileptic seizures by sending alerts to users and their trusted contacts when seizure risk is elevated. This solution aims to significantly enhance the quality of life for individuals with epilepsy by providing timely warnings that can help prevent injury and improve safety.

The startup develops plug-and-play RNA devices for non-invasive diagnostics and targeted therapies, enabling in situ disease detection from blood samples. Their technology facilitates early cancer diagnosis and the development of disease-specific therapeutic drugs, improving patient monitoring and surgical assistance.

MOWOOT is a class IIa medical device that utilizes intermittent colon exo-peristaltic therapy to stimulate intestinal transit, providing a natural and non-invasive solution for chronic constipation. Clinical trials have shown that MOWOOT significantly improves bowel health and increases the frequency of bowel movements in users.

The startup develops a biotechnology device specifically designed for ostomy patients, enabling self-management without the need for additional surgical procedures. This device offers features such as auto-replaceability, enhancing patient comfort and improving daily life quality.

Peptomyc develops cell-penetrating mini-proteins that directly inhibit MYC, a critical transcription factor involved in cancer proliferation and resistance. By targeting MYC dysregulation, which occurs in approximately 70% of cancers, Peptomyc aims to improve treatment efficacy and patient outcomes across various cancer types.

ProVerum Medical develops minimally invasive devices utilizing a proprietary technology to treat benign prostatic hyperplasia, a condition that causes urinary obstruction in men. Their approach aims to reduce patient recovery time and minimize complications associated with traditional surgical methods.

Renalyse develops a low-cost diagnostic platform that utilizes a drop of blood to monitor key kidney function indicators, enabling early detection of chronic kidney disease. This technology enhances patient management by facilitating remote health monitoring and improving treatment efficiency through real-time data exchange with healthcare providers.